136 related articles for article (PubMed ID: 20382181)
1. Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics.
Sun MK; Alkon DL
Pharmacol Ther; 2010 Jul; 127(1):66-77. PubMed ID: 20382181
[TBL] [Abstract][Full Text] [Related]
2. Activation of protein kinase C isozymes for the treatment of dementias.
Sun MK; Alkon DL
Adv Pharmacol; 2012; 64():273-302. PubMed ID: 22840750
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of chronic bryostatin-1 and alpha-tocopherol on spatial learning and memory in rats.
Sun MK; Alkon DL
Eur J Pharmacol; 2008 Apr; 584(2-3):328-37. PubMed ID: 18313045
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C pharmacology: perspectives on therapeutic potentials as antidementic and cognitive agents.
Sun MK; Alkon DL
Recent Pat CNS Drug Discov; 2006 Jun; 1(2):147-56. PubMed ID: 18221200
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C activators as synaptogenic and memory therapeutics.
Sun MK; Alkon DL
Arch Pharm (Weinheim); 2009 Dec; 342(12):689-98. PubMed ID: 19899099
[TBL] [Abstract][Full Text] [Related]
6. The "memory kinases": roles of PKC isoforms in signal processing and memory formation.
Sun MK; Alkon DL
Prog Mol Biol Transl Sci; 2014; 122():31-59. PubMed ID: 24484697
[TBL] [Abstract][Full Text] [Related]
7. Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair.
Nelson TJ; Sun MK; Hongpaisan J; Alkon DL
Eur J Pharmacol; 2008 May; 585(1):76-87. PubMed ID: 18402935
[TBL] [Abstract][Full Text] [Related]
8. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease.
Alkon DL; Sun MK; Nelson TJ
Trends Pharmacol Sci; 2007 Feb; 28(2):51-60. PubMed ID: 17218018
[TBL] [Abstract][Full Text] [Related]
9. Characterization and differential distribution of the three major human protein kinase C isozymes (PKC alpha, PKC beta, and PKC gamma) of the central nervous system in normal and Alzheimer's disease brains.
Clark EA; Leach KL; Trojanowski JQ; Lee VM
Lab Invest; 1991 Jan; 64(1):35-44. PubMed ID: 1990207
[TBL] [Abstract][Full Text] [Related]
10. Aniracetam improves contextual fear conditioning and increases hippocampal gamma-PKC activation in DBA/2J mice.
Smith AM; Wehner JM
Hippocampus; 2002; 12(1):76-85. PubMed ID: 11918291
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective versus tumorigenic protein kinase C activators.
Nelson TJ; Alkon DL
Trends Biochem Sci; 2009 Mar; 34(3):136-45. PubMed ID: 19233655
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
13. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
Ostrovskaya RU; Gruden MA; Bobkova NA; Sewell RD; Gudasheva TA; Samokhin AN; Seredinin SB; Noppe W; Sherstnev VV; Morozova-Roche LA
J Psychopharmacol; 2007 Aug; 21(6):611-9. PubMed ID: 17092975
[TBL] [Abstract][Full Text] [Related]
14. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.
Moriguchi S; Han F; Shioda N; Yamamoto Y; Nakajima T; Nakagawasai O; Tadano T; Yeh JZ; Narahashi T; Fukunaga K
J Neurochem; 2009 Jul; 110(1):170-81. PubMed ID: 19457128
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding.
Parvathy S; Ehrlich M; Pedrini S; Diaz N; Refolo L; Buxbaum JD; Bogush A; Petanceska S; Gandy S
J Neurochem; 2004 Aug; 90(4):1005-10. PubMed ID: 15287907
[TBL] [Abstract][Full Text] [Related]
16. Lead (Pb(+2)) impairs long-term memory and blocks learning-induced increases in hippocampal protein kinase C activity.
Vázquez A; Peña de Ortiz S
Toxicol Appl Pharmacol; 2004 Oct; 200(1):27-39. PubMed ID: 15451305
[TBL] [Abstract][Full Text] [Related]
17. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y
Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C isozymes: memory therapeutic potential.
Sun MK; Alkon DL
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):541-52. PubMed ID: 16266287
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain.
Dwivedi Y; Pandey GN
J Pharmacol Exp Ther; 1999 Nov; 291(2):688-704. PubMed ID: 10525089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
